Pharmaceutical Manufacturing And Innovation Projects Speed Up
This article was originally published in PharmAsia News
Executive Summary
According to the China Pharmaceutical Technology Transfer Center and the China Pharmaceutical Technology Organization, a Dec. 7 national advanced pharmaceutical technology management training class will focus on process management in the pharmaceutical manufacturing and innovation project (PharmAsia News, Sep. 8, 2008) under the country's 11th Five-Year Plan (2006-2010). At present, work on the first batch of project applications has been completed and the acceptance list will be publicized soon. A total of 3,290 proposed projects for the second batch are under appraisal and classes will begin next year. Subjects cover pivotal technology research in new drug development, establishment of technology platforms for drug innovation and construction of new drug incubation centers for enterprises. (Click here for more - Chinese Language)
You may also be interested in...
China Kicks Off Pharmaceutical Manufacturing And Innovation Project
A task force comprising members from China's Ministry of Health and 10 governmental bodies has proposed pharmaceutical manufacturing and innovation guidelines under the national science and technology development program. The project has two key targets, first of which is the development of a batch of medical products that are safe, efficient, convenient and cheap to prevent and treat major diseases. The second is the development of innovative drugs with intellectual property rights and market competitiveness, building up of advanced technology platforms, as well as shaping new drug creativity and technology systems to support the nation's pharmaceutical innovation. (Click here for more - Chinese Language)
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.